Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer

From Concept to Reality

Serrano, Jose, MD, PhD*; Andersen, Dana K., MD*; Forsmark, Christopher E., MD; Pandol, Stephen J., MD; Feng, Ziding, PhD§; Srivastava, Sudhir, PhD, MPH; Rinaudo, Jo Ann S., PhD on behalf of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)

doi: 10.1097/MPA.0000000000001167
CPDPC Conference Reports

Research progress in diseases of the exocrine pancreas [chronic pancreatitis (CP), pancreatogenic diabetes mellitus, and pancreatic cancer] has been hampered by the disorders' heterogeneity, the limitations of previous small cross-sectional studies, the inability to safely obtain pancreatic tissue for study, and the lack of structured epidemiology tools, genetic testing, and biomarker development. Mechanism-based research of these diseases has suffered from the lack of systematically collected clinical measures in longitudinal cohort studies linked with biospecimens. Given the increasing incidence and prevalence of CP and its association to the development of pancreatic cancer, its complications, high mortality rate, and associated health care cost, the National Institute for Diabetes and Digestive and Kidney Diseases and the National Cancer Institute funded the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer to identify research gaps and foster multidisciplinary collaborations to better diagnose, characterize, and manage CP and its sequelae. The CPDPC structure, governance, and research objectives are described in this article. Studies undertaken by the CPDPC are described in other articles in this journal's issue.

From the *Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD;

Division of Gastroenterology, Department of Medicine, University of Florida Health Sciences Center, Gainesville, FL;

Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA;

§Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX; and

Cancer Biomarker Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD.

Received for publication July 16, 2018; accepted August 24, 2018.

Address correspondence to: Jose Serrano, MD, PhD, Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, 6707 Democracy Boulevard, Room 657, Bethesda, MD 20817 (e-mail: serranoj@nih.gov).

The CPDPC Consortium is cofunded by the National Cancer Institute and the National Institute of Diabetes and Digestive and Kidney Diseases (grants U01DK108334, U01DK108314, U01DK108288, U01DK108300, U01DK108326, U01DK108323, U01DK108320, U01DK108332, U01DK108327, U01DK108306 and U01DK108328). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

The authors declare no conflict of interest.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.